Rigollier, Pascal
Novartis (Switzerland) · Novartis Institutes for BioMedical Research
2 papers on CoChat
Most cited papers
- Verified
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 150
- Verified
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors
Lorthiois, E., Gerspacher, M., Beyer, K. S., Vaupel, A., Leblanc, C., Stringer, R., Weiss, A., Wilcken, R., Guthy, D. A., Lingel, A., et al. (2022) · Journal of Medicinal Chemistry
Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity
Cited by 110
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free